Okta Inc. (NASDAQ: OKTA) reported a wider loss in the third quarter of 2020 due to an increase in costs and expenses despite a 45% surge in revenues. The bottom line was narrower than the analysts’ expectations while the top line missed consensus estimates.
Net loss was $63.5 million or $0.53 per share compared to a loss of $29.5 million or $0.27 per share in the previous year quarter. Adjusted loss per share widened to $0.07 from $0.04 a year ago.
Revenue grew by 45% to $153 million. Subscription revenue surged by 48% to $144.5 million. The results reflected the growing importance of identity.
Looking ahead into the fourth quarter, the company expects revenue to grow 34% to 35% to a range of $155 million to $156 million, and adjusted net loss per share of $0.05 to $0.04. Adjusted operating loss is predicted to be $10.1 million to $9.1 million.
For fiscal 2020, the company lifted its revenue outlook to the range of $574-575 million from the previous range of $560-563 million. Adjusted loss guidance is narrowed to the range of $0.35-0.34 per share from the prior range of $0.44-0.42 per share.
For the third quarter, total remaining performance obligations (RPO) soared by 68% year-over-year to $1.03 billion. The current RPO, which is revenue expected to be recognized over the next 12 months, jumped by 52% to $515.9 million.
The company experienced industry-leading growth in subscription revenue, remaining performance obligations, and billings. This was driven by the strong execution and the continued secular tailwinds of increasing adoption of cloud applications, digital transformation, and deployment of zero-trust security environments.
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company